​

Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TNDM Stock Forecast

Tandem Diabetes Care (TNDM) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $49.80, with a high of $65.00 and a low of $37.00. This represents a 35.73% increase from the last price of $36.69.

$25 $33 $41 $49 $57 $65 High: $65 Avg: $49.8 Low: $37 Last Closed Price: $36.69

TNDM Stock Rating

Tandem Diabetes Care stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (64.71%), 5 Hold (29.41%), 1 Sell (5.88%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 1 5 11 Strong Sell Sell Hold Buy Strong Buy

TNDM Price Target Upside V Benchmarks

TypeNameUpside
StockTandem Diabetes Care35.73%
SectorHealthcare Stocks 25.00%
IndustryMedical Device Stocks6.94%

Price Target Trends

1M3M12M
# Anlaysts1319
Avg Price Target$44.00$41.00$48.68
Last Closing Price$36.69$36.69$36.69
Upside/Downside19.92%11.75%32.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 254116-122
Jan, 254117-123
Dec, 244117-123
Nov, 2431171224
Oct, 2451061224
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 08, 2025Lee HambrightBernstein$44.00$37.4917.36%19.92%
Nov 07, 2024Jeff JohnsonRobert W. Baird$37.00$32.8712.56%0.84%
Nov 05, 2024Lee HambrightBernstein$42.00$33.1126.85%14.47%
Oct 04, 2024David RomanGoldman Sachs$46.00$39.9915.03%25.37%
Oct 02, 2024Shagun SinghRBC Capital$65.00$41.0758.27%77.16%
Aug 08, 2024William PlovanicCanaccord Genuity$57.00$37.0453.89%55.36%
Aug 05, 2024Matt MiksicBarclays$58.00$41.6739.19%58.08%
Aug 02, 2024Matt O'BrienPiper Sandler$55.00$35.2156.21%49.90%
Aug 02, 2024Jeff JohnsonRobert W. Baird$39.00$35.2110.76%6.30%
Jun 10, 2024Steven LichtmanOppenheimer$58.00$47.0323.33%58.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025BernsteinOutperformOutperformhold
Nov 05, 2024BernsteinOutperforminitialise
Oct 04, 2024Goldman SachsNeutralinitialise
Oct 02, 2024RBC CapitalOutperforminitialise
Oct 01, 2024CitigroupBuyBuyhold
Sep 23, 2024Wells FargoBuyBuyhold
Aug 22, 2024Morgan StanleyEqual-Weightinitialise
Aug 08, 2024Canaccord GenuityBuyinitialise
Aug 05, 2024BarclaysOverweightOverweighthold
Aug 02, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.56$0.25$-1.47$-3.43-----
Avg Forecast$-0.72$0.30$-1.09$-3.21$-1.69$-1.22$-0.76$-0.27$-0.07
High Forecast$-0.76$0.30$-1.13$-3.39$-1.77$-1.43$-1.08$-0.66$-0.07
Low Forecast$-0.70$0.32$-1.07$-2.99$-1.35$-0.78$-0.19$0.34$-0.06
Surprise %-22.22%-16.67%34.86%6.85%-----

Revenue Forecast

$450M $640M $830M $1B $1B $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$498.83M$702.80M$801.22M$747.72M-----
Avg Forecast$472.10M$691.83M$802.00M$764.45M$909.25M$1.01B$1.13B$1.25B$1.37B
High Forecast$463.07M$678.59M$790.66M$755.55M$902.72M$999.97M$1.12B$1.23B$1.34B
Low Forecast$495.47M$726.08M$823.70M$768.90M$935.20M$1.03B$1.13B$1.27B$1.40B
Surprise %5.66%1.59%-0.10%-2.19%-----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-34.38M$15.57M$-94.59M$-222.61M-----
Avg Forecast$-13.42M$20.84M$21.80M$-222.61M$-101.26M$-78.17M$-44.51M$-14.71M$-4.22M
High Forecast$-22.38M$13.95M$13.99M$-310.15M$-114.70M$-92.69M$-70.45M$-43.04M$-4.35M
Low Forecast$-4.46M$27.73M$29.60M$-135.07M$-87.83M$-50.98M$-12.35M$22.31M$-4.13M
Surprise %156.18%-25.30%-533.97%------

TNDM Forecast FAQ

Is Tandem Diabetes Care stock a buy?

Tandem Diabetes Care stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Tandem Diabetes Care is a favorable investment for most analysts.

What is Tandem Diabetes Care's price target?

Tandem Diabetes Care's price target, set by 17 Wall Street analysts, averages $49.8 over the next 12 months. The price target range spans from $37 at the low end to $65 at the high end, suggesting a potential 35.73% change from the previous closing price of $36.69.

How does Tandem Diabetes Care stock forecast compare to its benchmarks?

Tandem Diabetes Care's stock forecast shows a 35.73% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the medical device stocks industry (6.94%).

What is the breakdown of analyst ratings for Tandem Diabetes Care over the past three months?

  • February 2025: 18.18% Strong Buy, 50.00% Buy, 27.27% Hold, 0% Sell, 4.55% Strong Sell.
  • January 2025: 17.39% Strong Buy, 47.83% Buy, 30.43% Hold, 0% Sell, 4.35% Strong Sell.
  • December 2024: 17.39% Strong Buy, 47.83% Buy, 30.43% Hold, 0% Sell, 4.35% Strong Sell.

What is Tandem Diabetes Care’s EPS forecast?

Tandem Diabetes Care's average annual EPS forecast for its fiscal year ending in December is $-1.69 for 2024, a -50.73% decrease from the reported $-3.43 in 2023. The prediction for 2025 is $-1.22, $-0.76 for 2026, $-0.27 for 2027, and $-0.07 for 2028.

What is Tandem Diabetes Care’s revenue forecast?

Tandem Diabetes Care's average annual revenue forecast for its fiscal year ending in December is $909.25M for 2024, a 21.60% increase from the reported $747.72M in 2023. The forecast for 2025 is $1.01B, $1.13B for 2026, $1.25B for 2027, and $1.37B for 2028.

What is Tandem Diabetes Care’s net income forecast?

For its fiscal year ending in December, Tandem Diabetes Care's average annual net income forecast is $-101M for 2024, reflecting a -54.51% decrease from the reported $-223M in 2023. The projection for 2025 is $-78.171M, $-44.508M for 2026, $-14.707M for 2027, and $-4.223M for 2028.